Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01866163 · ClinicalTrials.gov registry record · Phase 3
LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris
A Phase 3 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 426
- Enrollment target
NCT01866163 is a Phase 3 study that has completed, run by LEO Pharma. The registered enrollment target is 426 participants.
The verdict
NCT01866163, a Phase 3 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 426 participants
- Enrollment target
Study Summary
The purpose of this trial is to compare the efficacy of treatment with LEO 90100 to that of treatment with vehicle for up to 4 weeks in subjects with psoriasis vulgaris.
Interventions
- DRUG Vehicle
- DRUG LEO 90100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 426 participants |
| Start Date | 2013-06 |
| Est. Completion | 2013-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01866163
The ClinicalTrials.gov registry entry for NCT01866163 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 426 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT01866163 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01866163 about?
NCT01866163 is a clinical study titled "LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris". The purpose of this trial is to compare the efficacy of treatment with LEO 90100 to that of treatment with vehicle for up to 4 weeks in subjects with psoriasis vulgaris.
What is the current status of trial NCT01866163?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 426 participants. The study started on 2013-06. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01866163?
The interventions under investigation include: Vehicle (DRUG), LEO 90100 (DRUG).
Who is sponsoring clinical trial NCT01866163?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.